MRC Laboratory of Molecular Biology
One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.
A technology platform to deliver cargoes using arrays of cell penetrating peptides was developed by the LMB’s Mike Gait, to help treat muscular degenerative diseases such as Duchenne muscular dystrophy. Further developments on this SELPEPCON technology, which was patented by the MRC and is licenced to Cambridge Research Biochemicals, are highlighted here.
Madan, from the LMB’s Structural Studies Division, will present his award lecture and receive the prestigious 2014 Colworth Medal at the Biochemical Society’s AGM, on Monday 1st December at Charles Darwin House, London. This article is no longer available from the source website.
Research by groups at Imperial College London and Michael Hastings’ group at LMB have revealed how local body clocks control waking and sleeping. A master clock found in part of the brain called the suprachiasmatic nucleus (SCN) is thought to synchronise lots of ‘local’ clocks that regulate many aspects of our metabolism, for example in the liver. But until now scientists have not had sufficient evidence to demonstrate the existence of these local clocks in the brain or how they operate. More…
The LMB has played a pivotal role in the development of X-ray crystallography and the inspirational work of crystallographic scientists from round the UK is showcased in an upcoming exhibition at the Royal Albert Hall. “Illuminating Atoms” presents a selection of photographs by Max Alexander, to celebrate the International Year of Crystallography. The exhibition can be viewed on the free open days on 15th, 16th and 29th November, or at performances until 7th December 2014. More…
Bicycle Therapeutics, founded as a spin out company from the LMB by Sir Greg Winter and Christian Heinis, has secured £20m equity financing to develop bicycle drug candidates for cancer treatment. The bio-therapeutics company has used its bicyclic peptide technology to discover a new class of drug candidates which are similar to antibodies but 100-fold smaller and manufactured using simple, economic chemical synthesis. More…
Professor Brian Clark, member of LMB Scientific Staff 1964-1974, and founder of structural biology research at Aarhus University, died on Monday 6 October 2014 aged 78 years. Brian led the team crystallising tRNA at LMB before moving to Aarhus. He was a very loyal supporter of LMB and recently attended the LMB alumni symposium in Cambridge. More…